# Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)

> **NCT02689362** · PHASE2 · COMPLETED · sponsor: **Eurofarma Laboratorios S.A.** · enrollment: 146 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Evogliptin
- **DRUG:** Sitagliptin
- **DRUG:** Placebo Evogliptin
- **DRUG:** Placebo Sitagliptin

## Key facts

- **NCT ID:** NCT02689362
- **Lead sponsor:** Eurofarma Laboratorios S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-08
- **Primary completion:** 2018-08-09
- **Final completion:** 2018-08-09
- **Target enrollment:** 146 (ACTUAL)
- **Last updated:** 2018-08-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02689362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02689362, "Evogliptin in Type 2 Diabetes Mellitus (EVOLUTION: EVOgLiptina no Diabetes Mellitus TIpO 2)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02689362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*